Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Urogenital Neoplasms 2Neoplasm Metastasis 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Metastatic Urothelial Cancer and Other Malignant Solid Tumors 1Metastatic Castration-resistant Prostate Cancer 1Male Urogenital Diseases 1Female Urogenital Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

sagopilone 1pembrolizumab 1glutamic acid diethyl ester 1enfortumab vedotin 1allantoicase 1Prednisolone 1Glutamine 1Glutamic Acid 1Exercise 1Dietary Supplements 1BID protein, human 1Acupuncture Therapy 1Acetylcarnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × enfortumab vedotin × Genitourinary × Clear all
NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡